Reduced Cross-Sectional Muscle Growth Six Months after Botulinum Toxin Type-A Injection in Children with Spastic Cerebral Palsy

Botulinum Neurotoxin type-A (BoNT-A) injections are widely used as first-line spasticity treatment in spastic cerebral palsy (SCP). Despite improved clinical outcomes, concerns regarding harmful effects on muscle morphology have been raised. Yet, the risk of initiating BoNT-A to reduce muscle growth...

Full description

Bibliographic Details
Main Authors: Nathalie De Beukelaer, Guido Weide, Ester Huyghe, Ines Vandekerckhove, Britta Hanssen, Nicky Peeters, Julie Uytterhoeven, Jorieke Deschrevel, Karen Maes, Marlies Corvelyn, Domiziana Costamagna, Ghislaine Gayan-Ramirez, Anja Van Campenhout, Kaat Desloovere
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Toxins
Subjects:
Online Access:https://www.mdpi.com/2072-6651/14/2/139